Orange、CAにおける急性骨髄性白血病の臨床試験

Orangeとその周辺地域（約30マイル以内）の拠点で、急性骨髄性白血病に関する13件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。

公式研究テキスト（英語）

ここで研究参加者を募集していますか？このページの上部に表示できます — 30日間 $99 →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

被験者募集中第2相

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

18歳以上 · 全性別 · 2026/10/05更新 · NCT05564390

Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

被験者募集中第2相

UCI Health Chao Family Comprehensive Cancer Center, Orange

18歳以上 · 全性別 · 2026/10/02更新 · NCT07304011

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

被験者募集中第3相

Children's Hospital of Orange County, Orange

6 Months – 21 Years · 全性別 · 2026/09/17更新 · NCT04293562

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

被験者募集中第1/2相

Children's Hospital of Orange County, Orange

22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

被験者募集中第1相

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

18歳〜75歳 · 全性別 · 2026/08/25更新 · NCT05886049

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

被験者募集中第3相

Children's Hospital of Orange County Main Campus - Orange, Orange

29 Days – 21 Years · 全性別 · 2026/08/24更新 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

被験者募集中第3相

University of California, Irvine, Orange

18歳以上 · 全性別 · 2026/08/20更新 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

被験者募集中第1相

UC Irvine Health Chao Family Comprehensive Cancer Center, Orange

18歳以上 · 全性別 · 2026/08/20更新 · NCT06001788

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

被験者募集中第1相

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange

18歳以上 · 全性別 · 2026/08/18更新 · NCT06656494

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

被験者募集中第4相

UCI Irvine Health, Orange

18歳以上 · 全性別 · 2026/08/11更新 · NCT07486713

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

被験者募集中観察研究

Children's Hospital of Orange County (CHOC), Orange

全年齢 · 全性別 · 2026/07/06更新 · NCT01351545

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

被験者募集中第2/3相

UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange

18歳以上 · 全性別 · 2026/04/30更新 · NCT04256317

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

被験者募集中第1相

UC Irvine Health Chao Family Comprehensive Cancer Center, Orange

18歳以上 · 全性別 · 2026/03/13更新 · NCT05735184

他の都市における急性骨髄性白血病の試験

Orangeにおける他の研究

ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。